drugset
drugset / Trial / NCT04928677

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

NCT04928677 ↗

Phase 1 Recruiting 50 enrolled Memorial Sloan Kettering Cancer Center Chugai Pharma USA · collab
NaSequentialOpen-labelTreatment

Summary

The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.

Timeline

Start
2021-06-09
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Codrituzumab Monoclonal antibody 10 mg/kg Intravenous
Subject Codrituzumab Monoclonal antibody 20 mg/kg Intravenous

Indications

No indication recorded.